Yahoo
NYSE - Delayed Quote USD

ResMed Inc. (RMD)

205.02 -8.79 (-4.11%)
At close: May 1 at 4:00:02 PM EDT
205.70 +0.68 (+0.33%)
After hours: May 1 at 7:54:12 PM EDT
Trade ResMed on Coinbase
Chart Range Bar
Loading chart for RMD

News headlines ResMed's recent performance shows robust growth, driven by strong product demand and strategic acquisitions. The company reported $1.43 billionin Q3 revenue, marking an 11% year-over-yearincrease, despite facing stock price declines.

ResMed's recent performance shows robust growth, driven by strong product demand and strategic acquisitions. The company reported $1.43 billionin Q3 revenue, marking an 11% year-over-yearincrease, despite facing stock price declines.

Updated 1m ago · Powered by Yahoo Scout
  • Previous Close 213.81
  • Open 206.00
  • Bid --
  • Ask --
  • Day's Range 198.64 - 206.84
  • 52 Week Range 198.64 - 293.81
  • Volume 2,826,146
  • Avg. Volume 1,135,311
  • Market Cap (intraday) 29.867B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) 19.77
  • EPS (TTM) 10.37
  • Earnings Date Apr 30, 2026
  • Forward Dividend & Yield 2.40 (1.17%)
  • Ex-Dividend Date May 14, 2026
  • 1y Target Est 273.40

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

www.resmed.com

10,600

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Performance Overview: RMD

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RMD
14.69%
S&P 500 (^GSPC)
5.62%

1-Year Return

RMD
12.53%
S&P 500 (^GSPC)
29.01%

3-Year Return

RMD
10.04%
S&P 500 (^GSPC)
73.47%

5-Year Return

RMD
13.87%
S&P 500 (^GSPC)
72.92%

Earnings Trends: RMD

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 1.43B
Earnings 417.17M

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500M
1B

Analyst Insights: RMD

View More

Analyst Price Targets

180.00 Low
273.40 Average
205.02 Current
340.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/1/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 314 -> 321

Statistics: RMD

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    29.87B

  • Enterprise Value

    29.05B

  • Trailing P/E

    19.77

  • Forward P/E

    17.36

  • PEG Ratio (5yr expected)

    1.26

  • Price/Sales (ttm)

    5.43

  • Price/Book (mrq)

    4.60

  • Enterprise Value/Revenue

    5.25

  • Enterprise Value/EBITDA

    13.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.44%

  • Return on Assets (ttm)

    14.71%

  • Return on Equity (ttm)

    25.25%

  • Revenue (ttm)

    5.54B

  • Net Income Avi to Common (ttm)

    1.52B

  • Diluted EPS (ttm)

    10.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.66B

  • Total Debt/Equity (mrq)

    12.99%

  • Levered Free Cash Flow (ttm)

    1.45B

Compare To: RMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: RMD

Fair Value

205.02 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: RMD

View More
  • ResMed Earnings: Slight Slowdown in US Devices, but Mask Sales Strong and Profitability Improving

    ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

    Rating
    Price Target
  • Lowering target price to $239.00

    RESMED INC has an Investment Rating of BUY; a target price of $239.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
  • Lowering target price to $243.00

    RESMED INC has an Investment Rating of BUY; a target price of $243.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
  • Raising target price to $254.00

    RESMED INC has an Investment Rating of BUY; a target price of $254.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: